Residency · Residency · Vascular Surgery
Cardiac Risk Assessment Before Vascular Surgery
Introduction
Patients undergoing vascular surgery often have a disproportionately high prevalence of coronary artery disease. Cardiac complications remain the leading cause of perioperative morbidity and mortality in this population. Therefore, systematic preoperative cardiac risk assessment is essential to identify high-risk patients, guide optimization strategies, and inform the decision-making process between open and endovascular surgical approaches.
Epidemiology of Cardiac Risk
Up to 60% of patients scheduled for vascular surgery have significant coronary artery disease. Perioperative myocardial infarction occurs in approximately 3% to 6% of open vascular procedures. Cardiac events account for about 40% to 60% of perioperative deaths following vascular surgery. This high risk is largely driven by shared atherosclerotic risk factors such as smoking, hypertension, diabetes, and dyslipidemia, which contribute to concurrent coronary and peripheral arterial disease.
Preoperative Cardiac Risk Stratification
Clinical Risk Indices
The Revised Cardiac Risk Index (RCRI), also known as the Lee Index, is a widely used tool that incorporates six independent predictors of major cardiac events. These include high-risk surgery (vascular surgery is classified as high risk), history of ischemic heart disease, history of congestive heart failure, history of cerebrovascular disease, insulin-dependent diabetes mellitus, and serum creatinine greater than 2.0 mg/dL. Based on the RCRI score, patients with 0 to 1 risk factors are considered low risk, with less than 1% chance of major adverse cardiac events (MACE). Those with a score of 2 fall into an intermediate risk category with a 3-7% risk, and a score of 3 or greater indicates high risk, with more than 10% likelihood of MACE.
| RCRI Score | Risk Category | Estimated MACE Rate | Approach |
|---|---|---|---|
| 0–1 | Low | <1% | Proceed to surgery |
| 2 | Intermediate | 3–7% | Consider functional capacity; testing if it will change management |
| ≥3 | High | >10% | Further evaluation; optimize medical therapy; consider endovascular alternative |
ACS/AHA Stepwise Approach
The American College of Cardiology and American Heart Association (ACC/AHA) recommend a stepwise approach to preoperative cardiac evaluation. The first step is to determine if the surgery is emergent; if so, surgery proceeds with concurrent risk-factor management and monitoring. The second step assesses whether the patient has an acute coronary syndrome; if present, surgery should be delayed for appropriate evaluation and treatment. The third step involves estimating perioperative risk using the RCRI and the surgical risk category. The fourth step evaluates functional capacity using metabolic equivalents (METs). Patients with a functional capacity of 4 METs or greater—such as those who can climb a flight of stairs or walk uphill—are considered to have adequate functional capacity and can proceed to surgery. Those with less than 4 METs or unknown functional capacity should be considered for further testing only if the results would change management. The fifth step recommends pharmacologic stress testing for patients with poor functional capacity and elevated risk.
Cardiac Testing Modalities
Noninvasive Stress Testing
Dobutamine stress echocardiography (DSE) evaluates wall motion abnormalities induced by pharmacologic stress, offering a sensitivity of approximately 80% and specificity of 84%. Nuclear myocardial perfusion imaging uses agents such as Thallium-201 or technetium-99m sestamibi combined with dipyridamole or adenosine to identify reversible ischemia. Exercise stress testing has limited utility in vascular surgery patients because claudication often prevents them from achieving target heart rates. Importantly, stress testing should only be performed when the results will influence clinical management, such as consideration of coronary revascularization or cancellation of the planned procedure.
Resting Echocardiography
Resting echocardiography is useful for assessing left ventricular ejection fraction (LVEF), valvular disease, and pulmonary hypertension. An LVEF below 30% independently predicts perioperative cardiac events. Significant aortic stenosis, defined as a mean gradient greater than 40 mmHg, requires thorough evaluation before elective surgery due to its high risk.
Cardiac Biomarkers
Preoperative measurement of brain natriuretic peptide (BNP) or its N-terminal prohormone (NT-proBNP) provides prognostic information independent of the RCRI. Elevated BNP levels above 100 pg/mL are associated with increased 30-day major adverse cardiac events and mortality. Routine preoperative troponin measurement is not recommended; however, postoperative monitoring of troponin is valuable for detecting myocardial injury.
Perioperative Cardiac Protection
Beta-Blockers
Beta-blockers should be continued in patients who are already receiving them, as abrupt withdrawal increases cardiac risk. However, initiating high-dose beta-blockers on the day of surgery is not recommended, as demonstrated by the POISE trial, which showed increased stroke and mortality with this practice. If beta-blockers are started de novo, they should be initiated at least seven days before surgery with careful dose titration to achieve a heart rate between 60 and 70 beats per minute.
Statins
Perioperative statin therapy reduces cardiac events and mortality in vascular surgery patients. Statins should be continued in patients already on them, and initiation should be considered two to four weeks before surgery in statin-naive patients. The benefits of statins extend beyond lipid lowering, including plaque stabilization and anti-inflammatory effects.
Antiplatelet Therapy
Aspirin is generally continued throughout the perioperative period in vascular surgery patients. For patients on dual antiplatelet therapy following coronary stenting, elective surgery should ideally be delayed for 30 days after bare-metal stent placement and six to twelve months after drug-eluting stent placement when possible. Decisions must balance bleeding risk against thrombotic risk and should be made in collaboration with cardiology.
Coronary Revascularization Before Vascular Surgery
The Coronary Artery Revascularization Prophylaxis (CARP) trial demonstrated no benefit from prophylactic coronary revascularization before vascular surgery in patients with stable coronary disease. Coronary revascularization is indicated only for patients with independent clinical indications such as left main disease, three-vessel disease with depressed LVEF, or acute coronary syndrome. Endovascular vascular procedures carry lower cardiac risk and may be preferred in high-risk patients.
Intraoperative and Postoperative Monitoring
Continuous electrocardiographic (ECG) monitoring with ST-segment analysis should be maintained during surgery and for 48 to 72 hours afterward. Serial troponin measurements at 24 and 48 hours postoperatively are recommended in high-risk patients. Maintaining hemodynamic stability is crucial, with avoidance of tachycardia (target heart rate less than 80 bpm), hypotension, and anemia. Myocardial injury after noncardiac surgery (MINS) is defined by troponin elevation with or without symptoms and carries a 30-day mortality rate of approximately 10%.
Key Clinical Pearls
All vascular surgery patients should be considered at elevated cardiac risk due to the shared burden of atherosclerotic disease. Functional capacity, measured in METs, is the single most important clinical predictor; patients who can climb a flight of stairs without symptoms generally have a favorable prognosis. Preoperative stress testing should be reserved for situations where the results will alter management decisions. The CARP trial established that prophylactic coronary revascularization does not improve outcomes before vascular surgery in stable patients. Perioperative statins and continuation of beta-blockers remain cornerstones of cardiac protection in this population.
References
- Fleisher LA, Fleischmann KE, et al. "2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management." J Am Coll Cardiol. 2014;64(22):e77-e137.
- McFalls EO, Ward HB, et al. "Coronary-artery revascularization before elective major vascular surgery (CARP trial)." N Engl J Med. 2004;351(27):2795-2804.
- Devereaux PJ, Yang H, et al. "Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial)." Lancet. 2008;371(9627):1839-1847.
- Defined, Defined, et al. "Perioperative statin therapy in vascular surgery: a meta-analysis." J Vasc Surg. 2015;61(3):818-826.